Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1

NCT03785249 is registered in ClinicalTrials.gov with Mirati Therapeutics Inc. as lead sponsor.

NCT NCT03785249
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03785249 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1
Lead sponsor
Mirati Therapeutics Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 15, 2019
Completion date
December 31, 2026
Enrollment
731 (actual)
Sites
222

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, malignant neoplastic disease, metastatic cancer